Pharmacovigilance is associated with drug safety which involves gathering, detecting, monitoring and preventing adverse reaction of drug. It mainly focuses on adverse drug reactions. The information accumulated from healthcare providers and patients plays a significant role in pharmacovigilance to transpire. The whole purpose of pharmacovigilance is to minimize the adverse effects of drugs on the patients.
Global pharmacovigilance market was valued USD 10 billion in 2027. The revenue of this market is projected to increase at CAGR of 13% during the forecast period.North America is the leading market for pharmacovigilance market globally with largest market 2014. Europe is a subsequent market owing to implementation of pharmacovigilance. Asia Pacific market is fastest growing market with highest CAGR accounted in 2014.
Increasing need of pharmacovigilance owing to increasing prevalence of adverse drug reaction is a major driving factor.Rise in intricacy of drug safety regulation by government is a growth factor for this market. Growing demand in paints & coating industry is one of the driving factor.
The global pharmacovigilance market according to clinical trial phase is segmented aspre-clinical, Phase I, Phase II, Phase IIIandPhase IV. The type of service provider segment consists of In-House and contract outsourcing. The market segments in terms of geographical regions include North America, Europe, Asia-Pacific andRest of the World(ROW).
This report provides:
1) An overview of the global market for pharmacovigilance and related technologies.
2) Analyses of global market trends, with data from 2019, estimates for 2020 and 2021, and projections of compound annual growth rates (CAGRs) through 2027.
3) Identifications of new market opportunities and targeted promotional plans for pharmacovigilance market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional markets for various types of coatings with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market.
Key players profiled in the report include:
• Quintiles Transnational Corporation
• Accenture Plc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb
• PAREXEL International Corporation
• Janssen Research & Development LLC
• Pharmaceutical Product Development Inc.
• United BioSource Corporation
• Synowlwedge LLC
• Cognizant Technology Solutions Corporation
• Covance Inc.
• ICON, Plc.
Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
The Pharmacovigilance Market has been segmented as below:
By Clinical Trial Phase
• Pre clinical
• Phase I
• Phase II
• Phase III
• Phase IV
By Type of Service Provider
• In- House
• Contract outsourcing
By Method
By End User
By Region
• North America
• Europe
• Asia Pacific
• Rest of the World (RoW)
Reasons to buy this Report:
1) Obtains the most up to date information available on all active and planned pharmacovigilance industry globally.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of pharmacovigilance industry and unit capacity data.
4) Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our New Reports :-
1. Introduction
1.1. Key Take Aways
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.3. Restraints
5. Pharmacovigilance Market, By Service Provider Analysis
5.1. Key Points
5.2. In-House
5.3. Contract Outsourcing
6. Pharmacovigilance Market, By Clinical Trial Phase Analysis
6.1. Key Points
6.2. Phase 1
6.3. Phase 2
6.4. Phase 3
6.5. Phase 4
6.6. Pre-Clinical
7. Pharmacovigilance Market, By Method
7.1. Key Points
7.2. Intensified ADR Reporting
7.3. Targeted Spontaneous Reporting
7.4. Cohort Event Monitoring
7.5. EHR Mining
7.6. Spontaneous Reporting
8. Pharmacovigilance Market, By End User
8.1. Key Points
8.2. Research Organizations
8.3. Industries
8.4. Hospitals
9. Pharmacovigilance Market, By Region
9.1. Key Points
9.2. North America
9.2.1. U.S
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. U.K
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Netherlands
9.3.7. Belgium
9.3.8. Rest of Europe
9.4. Asia Pacific
9.4.1. China
9.4.2. India
9.4.3. Japan
9.4.4. Australia
9.4.5. Rest of Asia Pacific
9.5. Rest of World
9.6. Competitive Landscape
9.7. Introduction
9.8. Recent Developments
9.8.1. Mergers & Acquisitions
9.8.2. New Product Developments
9.8.3. Portfolio/Production Capacity Expansions
9.8.4. Joint Ventures, Collaborations, Partnerships & Agreements
9.8.5. Others
10. Company Profile
10.1. Wipro Ltd
10.1.1. Company Overview
10.1.2. Product/Service Landscape
10.1.3. Financial Overview
10.1.4. Recent Developments
10.2. TAKE Solutions Ltd
10.2.1. Company Overview
10.2.2. Product/Service Landscape
10.2.3. Financial Overview
10.2.4. Recent Developments
10.3. United BioSource Corporation
10.3.1. Company Overview
10.3.2. Product/Service Landscape
10.3.3. Financial Overview
10.3.4. Recent Developments
10.4. PAREXEL International Corporation
10.4.1. Company Overview
10.4.2. Product/Service Landscape
10.4.3. Financial Overview
10.4.4. Recent Developments
10.5. ITClinical
10.5.1. Company Overview
10.5.2. Product/Service Landscape
10.5.3. Financial Overview
10.5.4. Recent Developments
10.6. Laboratory Corporation of America Holdings
10.6.1. Company Overview
10.6.2. Product/Service Landscape
10.6.3. Financial Overview
10.6.4. Recent Developments
10.7. IBM Corporation
10.7.1. Company Overview
10.7.2. Product/Service Landscape
10.7.3. Financial Overview
10.7.4. Recent Developments
10.8. ICON plc
10.8.1. Company Overview
10.8.2. Product/Service Landscape
10.8.3. Financial Overview
10.8.4. Recent Developments
10.9. Cognizant
10.9.1. Company Overview
10.9.2. Product/Service Landscape
10.9.3. Financial Overview
10.9.4. Recent Developments
10.10. Capgemini
10.10.1. Company Overview
10.10.2. Product/Service Landscape
10.10.3. Financial Overview
10.10.4. Recent Developments
10.11. Clinquest Group BV
10.11.1. Company Overview
10.11.2. Product/Service Landscape
10.11.3. Financial Overview
10.11.4. Recent Developments
10.12. ArisGlobal
10.12.1. Company Overview
10.12.2. Product/Service Landscape
10.12.3. Financial Overview
10.12.4. Recent Developments
10.13. BioClinica
10.13.1. Company Overview
10.13.2. Product/Service Landscape
10.13.3. Financial Overview
10.13.4. Recent Developments
10.14. Accenture
10.14.1. Company Overview
10.14.2. Product/Service Landscape
10.14.3. Financial Overview
10.14.4. Recent Developments
The Pharmacovigilance Market has been segmented as below:
By Clinical Trial Phase
• Pre clinical
• Phase I
• Phase II
• Phase III
• Phase IV
By Type of Service Provider
• In- House
• Contract outsourcing
By Method
By End User
By Region
• North America
• Europe
• Asia Pacific
• Rest of the World (RoW)
